Ionis Pharmaceuticals (IONS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IONS Ionis Pharmaceuticals

Watchlist

41.000
-0.830-1.98%

Close Sep 24 16:00 ET

43.000
+2.000+4.88%

Pre 08:16 ET

6.47BMarket Cap-16269P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Seeking AlphaSep 15 15:48 ET · Ratings
Jefferies Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Moomoo NewsSep 12 08:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)
TipRanksSep 12 08:20 ET · Ratings
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
WSJSep 12 07:00 ET
Leerink Partners Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $56
Moomoo NewsSep 11 02:31 ET · Ratings
Ionis Pharmaceuticals: A Buy Rating With a Lowered Price Target Amidst Strong Growth Prospects
TipRanksSep 11 02:06 ET · Ratings

Comments

Jaguar8

Apr 7 23:52

$Ionis Pharmaceuticals (IONS.US)$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”

Moomoo AI

Mar 17 10:16

Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Moomoo AI

Feb 29 08:12

Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.

Press Release: Ionis Announces New Chief Global Product Strategy Officer to Lead Next Phase of Commercial Growth

Moomoo AI

Feb 19 13:10

Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.

Insider Sellers Might Regret Selling Ionis Pharmaceuticals Shares at a Lower Price Than Current Market Value

Moomoo AI

Dec 29, 2023 02:22

Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

IONS Ionis Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target